Plasminogen Activator Inhibitor-1 in the Pathophysiology of Late Life Depression
- PMID: 39578639
- DOI: 10.1002/gps.70015
Plasminogen Activator Inhibitor-1 in the Pathophysiology of Late Life Depression
Abstract
Introduction: Late life depression (LLD) is characterized by specific clinical features including a high frequency of vascular form and frequent antidepressant treatment resistance. The expression and functions of the serine protease inhibitor, Plasminogen Activator Inhibitor-1 (PAI-1) is known to be altered by aging, vascular damage, insulin levels associated with a sedentary lifestyle, chronic stress leading to hypercortisolemia, and inflammatory changes linked to stress responses. These phenomena would be implicated in LLD like vascular depression. This article thus aims to review the existing literature regarding the association between LLD and plasmatic levels of PAI-1, a marker of hypofibrinolysis. We hypothesize that increased age would be associated with changes in PAI-1 plasma level and function which influence LLD pathogenesis and its treatment.
Results: Although a large number of studies on PAI-1 changes in the elderly exist, studies about its implications in LLD are sparse. Despite heterogeneous findings regarding the direction of variation in plasmatic PAI-1 levels among elderly participants with LLD, all studies demonstrated an association between PAI-1 levels and current or remitted depressive symptoms. Moreover, disruptions in the concentrations of other biological markers influencing PAI-1 expression, such as cytokines or adipokines, were also observed, notably an increase in the levels of interleukins 6 and 8.
Discussion: LLD genesis appears to be influenced by PAI-1 regulatory loops which are implicated in senescence or cell death. The resistance to antidepressant treatment appears to be linked to distinct biological profiles involving inflammatory and fibrinolytic factors. Taken together these data suggest that PAI-1 pathway may be a promising target of treatment development efforts for LLD, and depression in general.
Keywords: antidepressant resistance; late‐life depression; plasminogen activator inhibitor 1.
© 2024 John Wiley & Sons Ltd.
Similar articles
-
Increased expression of plasminogen activator inhibitor-1 (PAI-1) is associated with depression and depressive phenotype in C57Bl/6J mice.Exp Brain Res. 2019 Dec;237(12):3419-3430. doi: 10.1007/s00221-019-05682-0. Epub 2019 Nov 16. Exp Brain Res. 2019. PMID: 31734788
-
Antidepressant-like effect of n-3 PUFAs in CUMS rats: role of tPA/PAI-1 system.Physiol Behav. 2015 Feb;139:210-5. doi: 10.1016/j.physbeh.2014.11.054. Epub 2014 Nov 21. Physiol Behav. 2015. PMID: 25449400
-
Plasminogen activator inhibitor-1 is associated with leukocyte telomere length in American Indians: findings from the Strong Heart Family Study.J Thromb Haemost. 2017 Jun;15(6):1078-1085. doi: 10.1111/jth.13689. Epub 2017 May 3. J Thromb Haemost. 2017. PMID: 28378522 Free PMC article.
-
Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly.Cardiovasc Res. 2005 May 1;66(2):276-85. doi: 10.1016/j.cardiores.2004.11.013. Epub 2004 Dec 8. Cardiovasc Res. 2005. PMID: 15820196 Review.
-
Plasminogen activator inhibitor-1 in aging.Semin Thromb Hemost. 2014 Sep;40(6):652-9. doi: 10.1055/s-0034-1384635. Epub 2014 Aug 14. Semin Thromb Hemost. 2014. PMID: 25122500 Review.
Cited by
-
Novel Roles for Urokinase- and Tissue-Type Plasminogen Activators in the Pathogenesis of Mood Disorders.Int J Mol Sci. 2025 Jul 18;26(14):6899. doi: 10.3390/ijms26146899. Int J Mol Sci. 2025. PMID: 40725146 Free PMC article. Review.
References
-
- United Nations Department for Economic and Social Affairs, World Population Prospects 2022: Summary of Results (New York, NY, USA: Office of the Director, Population Division, United Nations, 2023).
-
- I. Sninate and A. Bennana, “Impact of Population Ageing on Medical Consumption: Compulsory Health Insurance in Morocco,” Pan African Medical Journal 35 (2020): 93, https://doi.org/10.11604/pamj.2020.35.93.20716.
-
- N. Abdoli, N. Salari, N. Darvishi, et al., “The Global Prevalence of Major Depressive Disorder (MDD) Among the Elderly: A Systematic Review and Meta‐Analysis,” Neuroscience and Biobehavioral Reviews 132 (2022): 1067–1073, https://doi.org/10.1016/j.neubiorev.2021.10.041.
-
- F. Chuquilín‐Arista, T. Álvarez‐Avellón, and M. Menéndez‐González, “Prevalence of Depression and Anxiety in Parkinson Disease and Impact on Quality of Life : A Community‐Based Study in Spain,” Journal of Geriatric Psychiatry and Neurology 33, no. 4 (2020): 207–213, https://doi.org/10.1177/0891988719874130.
-
- F. Leles da Costa Dias, A. L. Teixeira, H. Cerqueira Guimarães, et al., “Prevalence of Late‐Life Depression and its Correlates in a Community‐Dwelling Low‐Educated Population Aged 75+ Years: The Pietà Study,” Journal of Affective Disorders 242 (2019): 173–179, https://doi.org/10.1016/j.jad.2018.08.012.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous